For example, the targeting of TREM2, SPP1 and MARCO is currently under extensive investigation, and the first in vivo studies demonstrated promising results associated with the inhibition of immunosuppression and further decreased tumor growth [86, 95, 96]. This evidence concerns the gene TREM2 and neoplasm.